《新股表现》诺诚健华(09969.HK)开报9.4元 高上市价5%
诺诚健华-B(09969.HK)暗盘收10.22元高上市价14%;该股首挂开报9.4元,较上市价8.95元,高5%,市前成交3,232万股。
诺诚健华为内地生物医药公司。是次来港上市共发售2.5亿股,并已引入12名基石投资者合共认购1.25162亿股;10%公开发售获近300倍超购,已启动回拨机制占比增至50%,认购一手中签率25%;股份以招股范围(8.18-8.95元)上限定价,料集资净额20.93亿元,主要用作核心药物奥布替尼於内地及美国进行临床试验和商业化等工作提供资金、为两个临床阶段候选产品提供资金、为公司管线中6种IND(临床研究用新药或临床研究用新药申请)准备阶段候选药物研发提供资金等。上市联席保荐人分别为大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.